Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
about
Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathwayNovel delivery approaches for cancer therapeutics.A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesTargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway.Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation.Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignanciesDrug resistance in cancer: an overview.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanismEvaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype.Cell cycle control in acute myeloid leukemia.AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repairPhosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.Current therapeutic strategies for acute myeloid leukaemia.Mechanisms and insights into drug resistance in cancerMolecular targets and mechanisms of radiosensitization using DNA damage response pathways.4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumorsInhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsRole of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.Targeting DNA repair and the cell cycle in glioblastoma.DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications.A short update on cancer chemoresistance.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cellsG2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.Targeting Chk1 in the replicative stress response.Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.The Different Mechanisms of Cancer Drug Resistance: A Brief Review.The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.Chemotherapy-induced differential cell cycle arrest in B cell lymphomas affects their sensitivity to Wee1 inhibition.A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.
P2860
Q27302281-9FA5424B-2241-4C08-BE64-540E2969FA71Q30368171-84354C31-7ACB-4DDA-B5B1-68321045BAD6Q30431388-D86AFE26-1400-4B46-964A-D35697D4287DQ33493174-9D520978-0039-455F-BD3C-8E4E83F7F2EAQ34043049-ED1ECCAE-18E6-4C8D-AF61-8972428C829CQ34163011-EDF12338-9A7D-4D00-BF06-E26C5EE8E451Q34283002-35BAF20E-B025-4C39-A237-5BFE742113D5Q34367804-1599257E-E490-46B5-9365-5F9D1ED0B17FQ34437369-3E6F040A-52DD-4208-B0F7-FAE73408E928Q35679353-7D7F89D8-DB00-4014-BB6A-98413048E89EQ35990714-62113FA8-3311-4BE2-8467-6FEC91F9947FQ36009717-F21C8B6F-CEFE-4ED1-845F-59315EAA6842Q36206479-B79C10DC-A5AD-4202-B006-A8628B002373Q36413964-A62C6E36-D8D2-48D6-B803-38009FE756A8Q36461618-B93631E6-F5E4-448C-8AA6-ABCABB7DB65AQ36512934-D2455CC6-46D8-412B-88D7-1D053DC9FA40Q36539598-E8A2DAC1-C48B-4774-BA1B-B156896420C3Q36682301-74B00DE9-08A2-40CC-8353-1BF032DE059DQ36792626-371B40DA-B0E5-4F56-A091-CDCC5E54F3FFQ36965860-5E1F57AA-253F-4EBE-95E8-2FA706006D70Q37046021-2B4AC1F4-140A-4B8C-BEAE-6EEE78F5885AQ37168650-20CBE47E-8C2A-4E44-8BAF-9AC14B8E0844Q37499287-CE861776-2F0D-47A0-8627-935128797A06Q37641736-4FF75D35-82EF-4ECA-ACC9-C9D20FBB1E4AQ37642294-8AAD76CA-0111-488E-BAAF-E8FD590393FDQ37960389-8B3474C1-E264-480A-8E1C-4BA161C66A3EQ38121955-46E02F93-8917-46BD-A95F-EF1B365A61A5Q38253576-DDFFC9DF-3991-4A6A-9826-3903D8D51D0EQ38521775-07752C26-D7AC-47CB-905E-A06DC9E6CD82Q39142229-3707C7D6-52AF-4C6D-BBFF-304961613C87Q39301264-E9EF809C-32E9-47B7-898B-E6A3F9CC49E6Q39584277-1EF38B12-D72C-4C51-AE89-93932E3AFD74Q40021835-DFA9D727-881D-4327-8048-06285636CF7CQ41993531-9D7DCD1B-DC09-4E98-9E1B-4ED54D28D2F1Q42149280-CBFA9E8D-710C-4F9A-9FA0-7462F3A59266Q42658274-1F72445A-CFC2-4893-A8E4-171D99511934Q44601913-B971C63B-B775-4273-BC53-603441993A41Q47730914-524E33BA-324D-480A-8546-D8951E6C746DQ50020989-43A77054-52D1-4369-93E2-4AE5FCB9CAE2Q52680663-EB2D8CDF-B267-462A-8B50-7B0CBDB488C3
P2860
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@ast
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@en
type
label
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@ast
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@en
prefLabel
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@ast
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@en
P2093
P2860
P50
P1433
P1476
Pharmacodynamics of cytarabine ...... ro and during a clinical trial
@en
P2093
Deepa Sampath
Varsha Gandhi
P2860
P304
P356
10.1182/BLOOD-2005-08-3351
P407
P577
2005-11-17T00:00:00Z